DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma
S. K. Alam, Y. Zhang, L. Wang, Z. Zhu, C. E. Hernandez, Y. Zhou, N. Yang, J. Lei, X. Chen, L. Zeng, M. A. Klein, L. H. Hoeppner
This study identifies DARPP-32 as a mediator of ERBB3-driven resistance to EGFR TKIs in lung adenocarcinoma, showing its role in promoting oncogenic signaling and tumor progression.
bioRxiv · Feb 12, 2021Cancer Biology